Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xianguang Bai, Ming Yi, Ying Jiao, Qian Chu & Kongming Wu. (2019) Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. OncoTargets and Therapy 12, pages 9527-9538.
Read now
Read now
Hye In Kim, Mijin Kim, Se-Hoon Lee, So Young Park, Young Nam Kim, Hosu Kim, Min Ji Jeon, Tae Yong Kim, Sun Wook Kim, Won Bae Kim, Sang-We Kim, Dae Ho Lee, Keunchil Park, Myung-Ju Ahn, Jae Hoon Chung, Young Kee Shong, Won Gu Kim & Tae Hyuk Kim. (2018) Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer. OncoImmunology 7:1.
Read now
Read now
Wolfgang Hohenforst-Schmidt, Paul Zarogoulidis, Michael Steinheimer, Naim Benhassen, Chrysanthi Sardeli, Nikos Stalikas, Melpomeni Toitou & Haidong Huang. (2017) Second-line afatinib administration in an elderly patient with squamous cell carcinoma. Therapeutics and Clinical Risk Management 13, pages 341-343.
Read now
Read now
Articles from other publishers (23)
Jing Xiang, Xueni Liu, Yue Hao, Yanyan Zhu, Minhua Wu, Jian Lou, Yonghui Wang, Chunwei Xu, Yanru Xie & Jianhui Huang. (2023) Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency. Translational Oncology 38, pages 101787.
Crossref
Crossref
Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni, Francesco Pantano, Giuseppe Tonini & Bruno Vincenzi. (2023) Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. Current Oncology 30:2, pages 2366-2387.
Crossref
Crossref
Kriti Jain, Deepa Mehra, NirmalKumar Ganguly, Rashmi Rana, Surajit Ganguly & Shyam Aggarwal. (2023) Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer. Current Medicine Research and Practice 13:5, pages 232.
Crossref
Crossref
Kamila Wojas-Krawczyk, Iwona Paśnik, Tomasz Kucharczyk, Irena Wieleba, Natalia Krzyżanowska, Michał Gil, Paweł Krawczyk & Janusz Milanowski. (2021) Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy. International Journal of Molecular Sciences 22:17, pages 9133.
Crossref
Crossref
Saber Mehdizadeh, Hashem Bayatipoor, Salar Pashangzadeh, Roghayeh Jafarpour, Zeinab Shojaei & Morteza Motallebnezhad. (2021) Immune checkpoints and cancer development: Therapeutic implications and future directions. Pathology - Research and Practice 223, pages 153485.
Crossref
Crossref
Kamila Wojas-Krawczyk, Paweł Krawczyk, Michał Gil & Maciej Strzemski. (2021) Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts. Cancers 13:11, pages 2836.
Crossref
Crossref
Zixuan Du, Derui Yan, Zhongyang Li, Jincheng Gu, Ye Tian, Jianping Cao & Zaixiang Tang. (2020) Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer. Journal of Oncology 2020, pages 1-14.
Crossref
Crossref
Ji-yang Tan, Yi-chun Tang & Jie Huang. 2020. Gut Microbiota and Pathogenesis of Organ Injury. Gut Microbiota and Pathogenesis of Organ Injury
55
72
.
Sangeetha Palakurthi, Mari Kuraguchi, Sima J. Zacharek, Enrique Zudaire, Wei Huang, Dennis M. Bonal, Jeffrey Liu, Abha Dhaneshwar, Kristin DePeaux, Martha R. Gowaski, Dyane Bailey, Samuel N. Regan, Elena Ivanova, Catherine Ferrante, Jessie M. English, Aditya Khosla, Andrew H. Beck, Julie A. Rytlewski, Catherine Sanders, Sylvie Laquerre, Mark A. Bittinger, Paul T. Kirschmeier, Kathryn Packman, Pasi A. Janne, Christopher Moy, Kwok-Kin Wong, Raluca I. Verona & Matthew V. Lorenzi. (2019) The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. Cancer Immunology Research 7:9, pages 1457-1471.
Crossref
Crossref
Chen Zhu, Wilfred Villariza Espulgar, Woosik YooShohei KoyamaXiaoming DouAtsushi KumanogohEiichi Tamiya, Hyota TakamatsuMasato Saito. (2019) Single Cell Receptor Analysis Aided by a Centrifugal Microfluidic Device for Immune Cells Profiling. Bulletin of the Chemical Society of Japan.
Crossref
Crossref
De Zeng, Haoyu Lin, Jianxiong Cui & Weiquan Liang. (2019) TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinoma. Oncology Letters.
Crossref
Crossref
Li Ma, Jialin Lv, Yujie Dong, Xinyong Zhang, Xi Li, Hui Zhang, Jingying Nong, Quan Zhang, Na Qin, Xinjie Yang, Jinghui Wang & Shucai Zhang. (2019) PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. Interdisciplinary Sciences: Computational Life Sciences 11:2, pages 266-272.
Crossref
Crossref
Gautam Valecha, Manisha Pant, Uroosa Ibrahim & Jean P Atallah. (2017) Immunotherapy-induced autoimmune hypophysitis. Journal of Oncology Pharmacy Practice 25:1, pages 217-220.
Crossref
Crossref
Swadha Anand & Sharmila S. Mande. (2018) Diet, Microbiota and Gut-Lung Connection. Frontiers in Microbiology 9.
Crossref
Crossref
Yusuke Okuma, Hiroshi Wakui, Hirofumi Utsumi, Yukiko Sagawa, Yukio Hosomi, Kazuyoshi Kuwano & Sadamu Homma. (2018) Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer. Clinical Lung Cancer 19:5, pages 410-417.e1.
Crossref
Crossref
James C. Chen, Rolando Perez-Lorenzo, Yvonne M. Saenger, Charles G. Drake & Angela M. Christiano. (2018) IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy. Cell Systems 7:1, pages 92-103.e4.
Crossref
Crossref
Jin-Hua Chen, Jia-Lian Yang, Che-Yi Chou, Jiun-Yi Wang & Chin-Chuan Hung. (2018) Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer. Scientific Reports 8:1.
Crossref
Crossref
E. Jensen-Jarolim, H. J. Bax, R. Bianchini, S. Crescioli, T. R. Daniels-Wells, D. Dombrowicz, E. Fiebiger, H. J. Gould, S. Irshad, J. Janda, D. H. Josephs, F. Levi-Schaffer, L. O′Mahony, G. Pellizzari, M. L. Penichet, F. Redegeld, F. Roth-Walter, J. Singer, E. Untersmayr, L. Vangelista & S. N. Karagiannis. (2018) AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. Allergy 73:2, pages 328-340.
Crossref
Crossref
Alicia M Zukas & David Schiff. (2018) Neurological complications of new chemotherapy agents. Neuro-Oncology 20:1, pages 24-36.
Crossref
Crossref
Ivana Savić & Dejan Oprić. (2018) PD-1/PD-L1: A novel target for immunotherapy in patients with advanced and metastatic non-small cell lung cancer. Medicinski podmladak 69:2, pages 57-64.
Crossref
Crossref
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen & Haitao Zhao. (2017) PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Maria Giovanna Dal Bello, Angela Alama, Simona Coco, Irene Vanni & Francesco Grossi. (2017) Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discovery Today 22:8, pages 1266-1273.
Crossref
Crossref
Faezzah Baharom, Gregory Rankin, Anders Blomberg & Anna Smed-S?rensen. (2017) Human Lung Mononuclear Phagocytes in Health and Disease. Frontiers in Immunology 8.
Crossref
Crossref